Ed Damiano is a Professor of Biomedical Engineering at Boston University (BU), where he has held that role since 2004. His expertise and training are in the areas of mechanical and biomedical engineering and applied mechanics. Ever since his son was diagnosed with type 1 diabetes (T1D) at 11 months of age, he has been committed to creating and integrating closed-loop glycemic control technologies with a vision of building a bionic pancreas. This endeavor began with the design and development of mathematical algorithms to control blood glucose, which he and his team began testing in his laboratory at Boston University in 2005. These efforts led to the development of the iLet® bionic pancreas bionic pancreas. In 2015, Drs. Damiano and El-Khatib, along with Ed Raskin and Serafina Raskin, founded Beta Bionics, Inc. as a Massachusetts public benefit corporation with the goal of bringing the iLet bionic pancreas through clinical trials, regulatory clearance and into the hands of people with T1D.
Chairman of the Board:
Martha Goldberg Aronson
Martha Goldberg Aronson served as Executive Vice President and President-Global Healthcare, from September 2012 to November 2015 at Ecolab, Inc., a specialty chemical company. Prior to Ecolab, Ms. Goldberg Aronson served as Senior Vice President and President, North America, of Hill-Rom Holdings, Inc., a leading worldwide manufacturer and provider of medical technologies and related services for the health-care industry. Before joining Hill-Rom, she served as Senior Vice President at Medtronic, Inc., from March 2008 to November 2009, and in various other domestic and international general management positions with Medtronic throughout her 18 years at the company. She also serves as a director of Cardiovascular Systems Inc. and CONMED Corporation, where she is the Lead Independent Director. She previously served as a director of Hutchinson Technology, Methode Electronics and Clinical Innovations, LLC. Ms. Goldberg Aronson holds a BA degree in Economics from Wellesley College and an MBA degree from Harvard Business School.
Sean D. Carney
Sean Carney currently serves as a senior advisor with Hillhouse Capital. From 1996 to 2016, Mr. Carney was a Managing Director at Warburg Pincus, the global private equity firm. He has served on numerous public and private company boards, including Bausch + Lomb, Dexcom, Tornier, and Wright Medical. Prior to joining Warburg Pincus in 1996, Mr. Carney was a consultant with McKinsey & Company. Mr. Carney received an AB degree in economics from Harvard College and an MBA degree from Harvard Business School.
Jeff Hitchcock is the Founder and President of Children with Diabetes, an Ohio-based 501(c)(3) non-profit that provides education and support to families living with type 1 diabetes through its web site () and conferences throughout the United States and, in partnership with other non-profit organizations, in Canada and the United Kingdom. Since founding Children with Diabetes in 1995, Mr. Hitchcock and Children with Diabetes have hosted almost 100 conferences and educational events focused on improving the lives of families living with diabetes.
Finny Kuruvilla, MD, PhD
Finny Kuruvilla is the Chief Investment Officer for Eventide Funds, Lead Portfolio Manager for the Eventide Gilead Fund, and Portfolio Manager for the Eventide Healthcare & Life Sciences Fund. Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with Eventide, from 2008 through 2016, he was a Principal at Clarus Ventures, a leading healthcare and life sciences venture capital firm. Prior to joining Eventide, from 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT, and from 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women’s Hospital and Children’s Hospital Boston and a postdoctoral scientist at MIT. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry.
Corporate Project Vice President at Novo Nordisk
Platform Leader, Diabetes Development at Eli Lilly and Company
Managing Director, Technology Development at Boston University
Adam Steensberg, MD
Executive Vice President, Chief Medical and Development Officer for Zealand Pharma